Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Zoetis Belgium S.a

Abbott Laboratories Corporation

Eve H Barlow

Bernhard K Mueller

Martin Schmidt

Mary Leddy

Charles W Hutchins

Tariq Ghayur

Achim Moeller

Ravi Chari

Mario Mezler

Nicole Teusch

Reinhold Mueller

Emma Fung

Susan E Lacy

Meha Chhaya

Axel Meyer

Diane M Lang

Jeffrey A Barbon

Chung-Ming Hsieh

Philip D Bardwell

Mary R Leddy

Phillip D Bardwell

Susan E Lacey

Bernhard K MÜLLER

The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.

Caninized anti-NGF antibodies and their use

Anti-NGF antibodies and their use

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.

Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.

Antibodies against the RGM a protein and uses thereof

Antibodies against the RGM A protein and uses thereof

Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR)

Growing community of inventors

Wellesley, MA, United States of America

Eve H Barlow